Answers are grounded in this paper and cite their sources.
The 5-year survival rate for pancreatic ductal adenocarcinoma (PDAC) has remained at <5% for decades because no effective therapies have been identified. Integrin v6 is overexpressed in most PDAC and represents a promising therapeutic target. Thus, we attempted to develop an v6-specific peptide-drug conjugate (PDC) for therapy of PDAC. Methodology: We conjugated the DNA-binding pyrrolobenzodiazepine (PBD)-based payload SG3249 (tesirine) to an v6-specific 20mer peptide from the VP1 coat protein of foot-and-mouth-disease virus (FMDV) (forming conjugate SG3299) or to a non-targeting peptide (forming conjugate SG3511). PDCs were tested for specificity and toxicity on v6-negative versus-positive PDAC cells, patient-derived cell lines from tumor xenografts, and on two different in vivo models of PDAC. Immunohistochemical analyses were performed to establish therapeutic mechanism. Results: The v6-targeted PDC SG3299 was significantly more toxic (up to 78-fold) for v6-expressing versus v6-negative PDAC cell lines in vitro, and achieved significantly higher toxicity at equal dose than the non-targeted PDC SG3511 (up to 15-fold better). Moreover, SG3299 eliminated established (100mm 3 ) Capan-1 PDAC human xenografts, extending the lifespan of mice significantly (P=0.005). Immunohistochemistry revealed SG3299 induced DNA damage and apoptosis (increased H2AX and cleaved caspase 3, respectively) associated with significant reductions in proliferation (Ki67), 6 expression and PDAC tumour growth.
No takes yet. Share an insight, caveat, or question.
Moore et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: